Condition (MeSH)
Retinoschisis
ClinicalTrials.gov lists 18 trials for Retinoschisis or a narrower condition beneath it. National Eye Institute (NEI) has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
18 of the 18 trials are tagged with Retinoschisis itself; the rest are tagged with a narrower condition beneath it.
When did Retinoschisis trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 2 |
| 2017 | 1 |
| 2015 | 3 |
| 2014 | 2 |
| 2013 | 1 |
| 2012 | 2 |
| 2005 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Retinoschisis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 2 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 3 |
| Observational | 7 |
How many Retinoschisis trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 5 |
| Active, not recruiting | 1 |
| Completed | 12 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Retinoschisis trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Eye Institute (NEI) | 3 |
| Beacon Therapeutics | 2 |
| Atsena Therapeutics Inc. | 1 |
| InnoVec Biotherapeutics Inc. | 1 |
| Ray Therapeutics, Inc. | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Retinoschisis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| +/- Bupivacaine HCl | 1 |
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Dorzolamide 2% TID or brinzolamide 1% TID | 1 |
| RS1 AAV Vector | 1 |
| Triamcinolone 0.1% | 1 |
| ZM-01-L | 1 |
| rAAV2tYF-CB-hRS1 | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Retinoschisis trials report? (9)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Retinal detachment | 2 | 1 |
| Visual acuity reduced | 2 | 1 |
| Atrial Fibrillation | 1 | 1 |
| Cerebellar stroke | 1 | 1 |
| Faecaloma | 1 | 1 |
Showing 5 of 9 adverse events.
Which publications cover Retinoschisis? (23)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| LONG-TERM PROGRESSION PATTERN OF MYOPIC TRACTIONAL MACULOPATHY: Outcomes and Risk Factors. | Retina (Philadelphia, Pa.) | 2023 | Yes |
| Predominant Founder Effect among Recurrent Pathogenic Variants for an X-Linked Disorder. | Genes | 2022 | Yes |
| Of men and mice: Human X-linked retinoschisis and fidelity in mouse modeling. | Progress in retinal and eye research | 2022 | Yes |
| Targeted Expression of Retinoschisin by Retinal Bipolar Cells in XLRS Promotes Resolution of Retinoschisis Cysts Sans RS1 From Photoreceptors. | Investigative ophthalmology & visual science | 2022 | Yes |
| Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene therapy trial. | Molecular therapy : the journal of the American Society of Gene Therapy | 2021 | Yes |
Showing 5 of 23 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.